Cargando…

Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors

Background: Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Zortea, Karine, Franco, Viviane C., Francesconi, Lenise P., Cereser, Keila M. M., Lobato, Maria Inês R., Belmonte-de-Abreu, Paulo S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772037/
https://www.ncbi.nlm.nih.gov/pubmed/26840331
http://dx.doi.org/10.3390/nu8020073
_version_ 1782418493870702592
author Zortea, Karine
Franco, Viviane C.
Francesconi, Lenise P.
Cereser, Keila M. M.
Lobato, Maria Inês R.
Belmonte-de-Abreu, Paulo S.
author_facet Zortea, Karine
Franco, Viviane C.
Francesconi, Lenise P.
Cereser, Keila M. M.
Lobato, Maria Inês R.
Belmonte-de-Abreu, Paulo S.
author_sort Zortea, Karine
collection PubMed
description Background: Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ. Methods and Results: This is a four-week randomized, double-blind controlled trial (registration No.: NCT 02062190) in which 19 men with a diagnosis of SZ, aged 18 to 65, were assigned to either a resveratrol supplement group (200 mg/day) or a placebo group (200 mg/day). In short, we did not observe significant changes after resveratrol supplementation. In the placebo group, we found a significant increase in total cholesterol levels (p = 0.024) and in LDL-cholesterol (p = 0.002), as well as a decrease in body fat percentage (p = 0.038). The placebo group also showed an increase in triglycerides (9.19%) and a reduction in HDL-cholesterol (4.88%). In the resveratrol group, triglycerides decreased (7.64%). Conclusion: In summary, oral resveratrol in reasonably low dosages (200 mg daily) brought no differences to body weight, waist circumference, glucose, and total cholesterol. It was possible to note that the lipid profile in the placebo group worsened and, although no significant differences were found, we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels.
format Online
Article
Text
id pubmed-4772037
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-47720372016-03-08 Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors Zortea, Karine Franco, Viviane C. Francesconi, Lenise P. Cereser, Keila M. M. Lobato, Maria Inês R. Belmonte-de-Abreu, Paulo S. Nutrients Article Background: Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ. Methods and Results: This is a four-week randomized, double-blind controlled trial (registration No.: NCT 02062190) in which 19 men with a diagnosis of SZ, aged 18 to 65, were assigned to either a resveratrol supplement group (200 mg/day) or a placebo group (200 mg/day). In short, we did not observe significant changes after resveratrol supplementation. In the placebo group, we found a significant increase in total cholesterol levels (p = 0.024) and in LDL-cholesterol (p = 0.002), as well as a decrease in body fat percentage (p = 0.038). The placebo group also showed an increase in triglycerides (9.19%) and a reduction in HDL-cholesterol (4.88%). In the resveratrol group, triglycerides decreased (7.64%). Conclusion: In summary, oral resveratrol in reasonably low dosages (200 mg daily) brought no differences to body weight, waist circumference, glucose, and total cholesterol. It was possible to note that the lipid profile in the placebo group worsened and, although no significant differences were found, we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels. MDPI 2016-01-29 /pmc/articles/PMC4772037/ /pubmed/26840331 http://dx.doi.org/10.3390/nu8020073 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zortea, Karine
Franco, Viviane C.
Francesconi, Lenise P.
Cereser, Keila M. M.
Lobato, Maria Inês R.
Belmonte-de-Abreu, Paulo S.
Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors
title Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors
title_full Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors
title_fullStr Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors
title_full_unstemmed Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors
title_short Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors
title_sort resveratrol supplementation in schizophrenia patients: a randomized clinical trial evaluating serum glucose and cardiovascular risk factors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772037/
https://www.ncbi.nlm.nih.gov/pubmed/26840331
http://dx.doi.org/10.3390/nu8020073
work_keys_str_mv AT zorteakarine resveratrolsupplementationinschizophreniapatientsarandomizedclinicaltrialevaluatingserumglucoseandcardiovascularriskfactors
AT francovivianec resveratrolsupplementationinschizophreniapatientsarandomizedclinicaltrialevaluatingserumglucoseandcardiovascularriskfactors
AT francesconilenisep resveratrolsupplementationinschizophreniapatientsarandomizedclinicaltrialevaluatingserumglucoseandcardiovascularriskfactors
AT cereserkeilamm resveratrolsupplementationinschizophreniapatientsarandomizedclinicaltrialevaluatingserumglucoseandcardiovascularriskfactors
AT lobatomariainesr resveratrolsupplementationinschizophreniapatientsarandomizedclinicaltrialevaluatingserumglucoseandcardiovascularriskfactors
AT belmontedeabreupaulos resveratrolsupplementationinschizophreniapatientsarandomizedclinicaltrialevaluatingserumglucoseandcardiovascularriskfactors